Bispecific Antibody Market Trends

Growth Drivers

• Rising Approvals for Antibodies – The approval of antibodies provides healthcare providers with an additional treatment option for various diseases. At the start of November 2021, seven antibody products that addressed the COVID-19 virus, developed as either monotherapy or in combination with anti-SARS-CoV-2 mAbs, have been approved or had obtained emergency use authorizations (EUAs).
• Rising Benefits of Bispecific Antibody – According to the results of phase I/II clinical trial of REGN5459 reported at the AACR Annual Meeting 2023, patients with multiple myeloma that has recurred or who were treated with the two highest doses of REGN5459, a bispecific antibody addressing BCMA and CD3, saw a 90.5% overall response rate. The rising research and development have advanced the efficacy of bispecific antibodies for enhanced therapeutic compared to traditional monoclonal antibodies.
• Rising Advancement in Protein Engineering – In January 2022, Amgen collaborated with Generate Biomedicines, for discerning protein engineering and developing bioengineered protein drug for five new clinical trials targeting different areas. Bispecific antibodies have gained significant utility in the field of protein engineering owing to their use in binding the two different proteins, enabling the modulation of protein-protein interactions. This capability opens up possibilities for therapeutic interventions and functional studies in protein engineering.

Challenges

• The Drug Development is Expensive- The initial stage of drug development involves extensive research and discovery efforts, including target identification, compound screening, and preclinical testing. These activities require significant investment in scientific expertise, laboratory facilities, and equipment. R&D costs account for a substantial portion of the overall expenses in drug development.

• Lack of Adequate Healthcare Infrastructure
• Insufficient Medical Reimbursement Policies